Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment (Oncogene, (2021), 40, 44, (6248-6257), 10.1038/s41388-021-02020-z)

Dotan Moskovich, Yael Finkelshtein, Adi Alfandari, Amit Rosemarin, Tzuri Lifschytz, Avivit Weisz, Santanu Mondal, Harinarayana Ungati, Aviva Katzav, Debora Kidron, Govindasamy Mugesh, Martin Ellis, Bernard Lerer, Osnat Ashur-Fabian*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.

Original languageEnglish
Pages (from-to)1508
Number of pages1
JournalOncogene
Volume42
Issue number18
DOIs
StatePublished - 2 May 2023

Fingerprint

Dive into the research topics of 'Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment (Oncogene, (2021), 40, 44, (6248-6257), 10.1038/s41388-021-02020-z)'. Together they form a unique fingerprint.

Cite this